<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJPN</journal-id><journal-title-group><journal-title>International Journal of Psychiatry and Neurology</journal-title></journal-title-group><issn pub-type="epub">2166-5788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/IJPN.2017.63008</article-id><article-id pub-id-type="publisher-id">IJPN-21782</article-id><article-categories><subj-group subj-group-type="heading"><subject>IJPN20170300000_89812866.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  右美沙芬治疗特发性眼睑痉挛的回顾性分析
  A Retrospective Study on the Therapeutic Effect of Dextromethorphan on Essential Blepharospasm
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>学胜</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>上海交通大学医学院附属新华医院神经外科，上海</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>zhengxuesheng@xinhuamed.com.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>07</month><year>2017</year></pub-date><volume>06</volume><issue>03</issue><fpage>44</fpage><lpage>49</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   背景：眼睑痉挛是一种局限性肌张力障碍，患者眼睛周围的肌肉频繁不自主收缩导致眼睑闭合和视力障碍。目前治疗眼睑痉挛的效果并不是很理想。本文是一项右美沙芬对眼睑痉挛疗效的回顾性研究。方法：回顾性研究包括22例特发性眼睑痉挛，患者接受右美沙芬治疗，30mg 每天三次口服，采用扬科维奇评分(Jankovic Rating Scale, JRS)和眼睑痉挛的残疾指数(Blepharospasm Disability Index, BSDI)评价疗效。结果：右美沙芬治疗前基线JRS评分是5.55&#177;1.10分，BSDI基线评分为2.87&#177;0.59。右美沙芬治疗1周后，JRS评分下降到2.82 &#177; 0.85分，BSDI下降到1.36 &#177; 0.58分。在接下来的3周的治疗，JRS和BSDI得分保持在一个稳定的状态。停止右美沙芬治疗一周后，JRS评分(5.41 &#177; 1.01分)和BSDI评分(2.63 &#177; 0.64分)回到治疗前的基线水平。结论：本研究发现右美沙芬对眼睑痉挛患者有效，这一发现可能意味着另一种治疗选项。 Background: Blepharospasm is a focal dystonia characterized by intermittent or continual invo-luntary contractions of the facial muscles around both eyes. It causes frequent eyelid closure and visual disturbance. The current therapies for blepharospasm are not satisfactory. Here is a retrospective study to analyze the therapeutic effect of dextromethorphan on blepharospasm. Methods: This retrospective study included 22 patients with blepharospasm. They were treated with dextromethorphan, 30 mg orally three times a day for 4 weeks. The effect of dextromethorphan on essential blepharospasm was evaluated using Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI). Results: Before treatment, the baseline JRS score was 5.55 &#177; 1.10 points, and the BSDI score was 2.87 &#177; 0.59 points. After 1 week of dextromethorphan treatment, the JRS score decreased to 2.82 &#177; 0.85 points and the BSDI score to 1.36 &#177; 0.58 points. In the following 3 weeks of dextromethorphan treatment, the JRS and BSDI scores kept in a steady state. One week after the dextromethorphan treatment, the JRS (5.41 &#177; 1.01 points) and BSDI (2.63 &#177; 0.64 points) scores returned to the pre-treatment baseline level. Conclusion: We found that dextromethorphan is effective to relieve the symptoms in patients with blepharospasm, and this finding might imply an alternative treatment option to essential blepharospam.
    
  
 
</p></abstract><kwd-group><kwd>特发性眼睑痉挛，右美沙芬, Essential Blepharospasm</kwd><kwd> Dextromethorphan</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>右美沙芬治疗特发性眼睑痉挛的回顾性分析<sup> </sup></title><p>郑学胜</p><p>上海交通大学医学院附属新华医院神经外科，上海</p><p>收稿日期：2017年8月3日；录用日期：2017年8月17日；发布日期：2017年8月23日</p><disp-formula id="hanspub.21782-formula69"><graphic xlink:href="http://html.hanspub.org/file/6-2240075x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>背景：眼睑痉挛是一种局限性肌张力障碍，患者眼睛周围的肌肉频繁不自主收缩导致眼睑闭合和视力障碍。目前治疗眼睑痉挛的效果并不是很理想。本文是一项右美沙芬对眼睑痉挛疗效的回顾性研究。方法：回顾性研究包括22例特发性眼睑痉挛，患者接受右美沙芬治疗，30mg 每天三次口服，采用扬科维奇评分(Jankovic Rating Scale, JRS)和眼睑痉挛的残疾指数(Blepharospasm Disability Index, BSDI)评价疗效。结果：右美沙芬治疗前基线JRS评分是5.55&#177;1.10分，BSDI基线评分为2.87&#177;0.59。右美沙芬治疗1周后，JRS评分下降到2.82 &#177; 0.85分，BSDI下降到1.36 &#177; 0.58分。在接下来的3周的治疗，JRS和BSDI得分保持在一个稳定的状态。停止右美沙芬治疗一周后，JRS评分(5.41 &#177; 1.01分)和BSDI评分(2.63 &#177; 0.64分)回到治疗前的基线水平。结论：本研究发现右美沙芬对眼睑痉挛患者有效，这一发现可能意味着另一种治疗选项。</p><p>关键词 :特发性眼睑痉挛，右美沙芬</p><disp-formula id="hanspub.21782-formula70"><graphic xlink:href="http://html.hanspub.org/file/6-2240075x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>眼睑痉挛是一种局限性肌张力障碍，患者眼睛周围的肌肉频繁不断的不自主收缩，导致眼睑闭合和视力障碍，影响日常生活和工作。严重的眼睑痉挛可能引起交通事故 [<xref ref-type="bibr" rid="hanspub.21782-ref1">1</xref>] 。由于特发性眼睑痉挛的发病机制不明，目前的治疗主要是缓解症状 [<xref ref-type="bibr" rid="hanspub.21782-ref2">2</xref>] 。许多治疗方法，如生物反馈、催眠、针灸、心理疗法都已经在临床试用过，但收效甚微。一些药物如左旋多巴，丁苯那嗪、安定、氯硝西泮、碳酸锂、哌啶醇、苯妥英、盐酸金刚烷胺也一直临床试用，以期缓解痉挛症状，但效果很差 [<xref ref-type="bibr" rid="hanspub.21782-ref3">3</xref>] 。根据临床经验，我们在临床实践中使用右美沙芬治疗眼睑痉挛，发现右美沙芬对眼睑痉挛患者缓解症状有效，因此我们在此回顾性分析该系列病例。</p></sec><sec id="s4"><title>2. 病例和方法</title><p>病例：2014年一位男性眼睑痉挛患者向我们反映，他偶然发现，当他得了上呼吸道感染后服用非处方镇咳药右美沙芬，其眼睑痉挛症状得到明显减轻。2015年1月至2016年12月期间，22例特发性眼睑痉挛患者在我科门诊接受右美沙芬治疗，30 mg每日三次口服，4周为一疗程。十五女性患者，七个男性患者，年龄在42至67岁之间(平均58.3岁)，均由神经外科专家排除其它疾患确诊为特发性眼睑痉挛，排除严重内脏功能障碍和精神病，排除颅神经手术史。右美沙芬治疗期间，禁用其他用药，除非高血压、糖尿病患者长期使用的降压、降糖药。治疗前一周、治疗过程中每一周及治疗后一周，根据扬科维奇评分(Jankovic Rating Scale, JRS)和眼睑痉挛的残疾指数(Blepharospasm Disability Index, BSDI)，评价眼睑痉挛的程度。同时记录任何副作用。</p><p>JRS：该评分表由神经外科医生评估 [<xref ref-type="bibr" rid="hanspub.21782-ref4">4</xref>] ，该量表包括严重程度和频率两方面。严重程度方面，得分0意味着没有痉挛，得分1意味着只有在外部刺激下才出现眨眼增加，得分2意味着轻度自发的眼睑抽动，得分3意味着中度痉挛，得分4意味着严重痉挛。作为频率方面，0分意味着没有痉挛，1分意味着增加的闭眼频率，2分意味着眼睑轻度抽搐，但持续 &lt; 1秒，得分3意味着眼睑痉挛持续 &gt; 1秒，4分意味着因持续闭目而功能性失明。因此，JRS总分为8。</p><p>BSDI：BSDI是患者自评量表 [<xref ref-type="bibr" rid="hanspub.21782-ref4">4</xref>] 。它包括6个项目，即驾驶车辆，阅读，看电视，购物，散步和做日常活动。对于每一个项目，得分0意味着没有障碍，得分1意味着轻微的障碍，得分2意味着中度障碍，得分3意味着严重的障碍，得分4意味着完全不能做这项活动。如果一个项目不适用于一个病人，例如，一个没有驾驶执照的病人“驾驶车辆”的项目，该项目应该被删除。最后分数是所有适用活动得分的平均分数。因此，BSDI得分范围是0~4。</p><p>统计分析：t检验和方差分析用于定量数据分析。P &lt; 0.05者有统计学意义。</p></sec><sec id="s5"><title>3. 结果</title><p>表1列明了22例眼睑痉挛患者在不同时间点的JRS和BSDI评分。</p><p>右美沙芬治疗前我们检测了患者的基线评分，JRS基线评分是5.55 &#177; 1.10分，BSDI基线评分为2.87 &#177; 0.59。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> JRS and BSDI scores of 22 essential blepharospasm patients receiving dextromethorphan treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >治疗前</th><th align="center" valign="middle"  colspan="2"  >治疗1周</th><th align="center" valign="middle"  colspan="2"  >治疗2周</th><th align="center" valign="middle"  colspan="2"  >治疗3周</th><th align="center" valign="middle"  colspan="2"  >治疗4周</th><th align="center" valign="middle"  colspan="2"  >治疗后</th></tr></thead><tr><td align="center" valign="middle" >病例号</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td><td align="center" valign="middle" >JRS</td><td align="center" valign="middle" >BSDI</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3.5</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.3</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.1</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3.6</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.6</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.9</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.7</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.8</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.7</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.3</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3.8</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.4</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.4</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.8</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.8</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.4</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.7</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.2</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.6</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.6</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.2</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.1</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.8</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.6</td></tr></tbody></table></table-wrap><p>表1. 22例特发性眼睑痉挛患者接受右美沙芬治疗的JRS和BSDI评分</p><p>图1. 特发性眼睑痉挛患者右美沙芬治疗的平均JRS和BSDI评分</p><p>右美沙芬治疗1周后，JRS评分下降到2.82 &#177; 0.85分，BSDI下降到1.36 &#177; 0.58分。与治疗前基线相比，JRS (P &lt; 0.05)和BSDI (P &lt; 0.05)的改善都具有统计学意义。</p><p>如图1所示，在接下来的3周的治疗，JRS和BSDI得分保持在一个稳定的状态，没有显著性改变 (P &gt; 0.05)。</p><p>停止右美沙芬治疗一周后，JRS评分(5.41 &#177; 1.01分)和BSDI评分(2.63 &#177; 0.64分)回到治疗前的基线水平。</p><p>本组无严重并发症。两名患者有轻度头晕，1例有轻度恶心，这些副作用是可耐受的，并未导致右美沙芬停药。</p></sec><sec id="s6"><title>4. 讨论</title><p>由于特发性眼睑痉挛的发病机制尚不清楚，当前治疗的主要目的是缓解痉挛症状。</p><p>最常见的治疗方法是A型肉毒毒素注射。肉毒杆菌毒素治疗特发性眼睑痉挛的短期表现是很成功的，其不良事件少见。但是肉毒杆菌神经毒素对于机体免疫系统是一种外源性抗原，会引发特异性抗体的产生，最终肉毒杆菌毒素将被中和。因此，肉毒杆菌神经毒素注射一般开始是有效的，但会在几年内耐药 [<xref ref-type="bibr" rid="hanspub.21782-ref5">5</xref>] 。</p><p>特发性眼睑痉挛的手术治疗效果不理想。脑深部电刺激(DBS)，部分面神经切断术，面肌悬吊术都曾在临床尝试，在某种程度上缓解症状，但不能治愈 [<xref ref-type="bibr" rid="hanspub.21782-ref6">6</xref>] 。</p><p>如上所述，各种口服药物的症状缓解效果非常有限。我们偶然从临床实践发现，镇咳药右美沙芬能抑制眼睑痉挛。这可能成为非手术治疗的新选择，当然需要未来前瞻性的临床试验。</p><p>作为镇咳药，右美沙芬可能是作用于中枢神经系统以提高咳嗽阈值 [<xref ref-type="bibr" rid="hanspub.21782-ref7">7</xref>] 。它能减轻谷氨酸诱导的神经毒性，对缺血引起的脑损伤具有神经保护作用 [<xref ref-type="bibr" rid="hanspub.21782-ref8">8</xref>] 。右美沙芬还有许多其他医疗应用，如疼痛缓解，精神疾病治疗，以及成瘾的治疗 [<xref ref-type="bibr" rid="hanspub.21782-ref9">9</xref>] 。</p><p>右美沙芬的药理作用十分广泛。它是一种非选择性5-羟色胺再摄取抑制剂和σ-1受体激动剂，也是一个低亲和力的非竞争性NMDA受体(NMDA受体)拮抗剂 [<xref ref-type="bibr" rid="hanspub.21782-ref10">10</xref>] 。它能抑制突触前末梢投射到二级神经元的谷氨酸释放 [<xref ref-type="bibr" rid="hanspub.21782-ref11">11</xref>] 。虽然右美沙芬在中枢神经系统中具有广泛的药理作用，但确切的作用点和作用机制尚不完全清楚。已被证明在眼睑痉挛患者中，很多大脑区域功能异常，包括基底神经节，皮层和小脑。然而，目前尚不清楚这些部位的功能变化是否是该病的病因或结果 [<xref ref-type="bibr" rid="hanspub.21782-ref2">2</xref>] 。参与特发性眼睑痉挛发病的神经回路和确切机制尚不明确，因此研究右美沙芬如何治疗眼睑痉挛还有很大的空间。</p><p>作为一项回顾性分析，本文存在局限：只有治疗前后的自身对照，没有随机对照。在将来的前瞻性研究中需要克服该缺陷。</p></sec><sec id="s7"><title>5. 结论</title><p>本研究发现右美沙芬对眼睑痉挛患者有效，并且无明显严重副作用。这一发现可能意味着另一种治疗选项。</p></sec><sec id="s8"><title>基金项目</title><p>本研究得到上海市科委项目(14DZ1930303)的资助。</p></sec><sec id="s9"><title>文章引用</title><p>郑学胜. 右美沙芬治疗特发性眼睑痉挛的回顾性分析 A Retrospective Study on the Therapeutic Effect of Dextromethorphan on Essential Blepharospasm[J]. 国际神经精神科学杂志, 2017, 06(03): 44-49. http://dx.doi.org/10.12677/IJPN.2017.63008</p></sec><sec id="s10"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.21782-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Huang, X.F., Wang, K.Y., Liang, Z.H., Du, R.R. and Zhou, L.N. (2015) Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China. European Neurology, 73, 337-341.  
&lt;br&gt;https://doi.org/10.1159/000381707</mixed-citation></ref><ref id="hanspub.21782-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Valls-Sole, J. and Defazio, G. (2016) Blepharospasm: Update on Epidemiology, Clinical Aspects, and Pathophysiology. Frontiers in Neurology, 7, 45. &lt;br&gt;https://doi.org/10.3389/fneur.2016.00045</mixed-citation></ref><ref id="hanspub.21782-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Coscarelli, J.M. (2010) Essential Blepharospasm. Seminars in Ophthalmology, 25, 104-108.  
&lt;br&gt;https://doi.org/10.3109/08820538.2010.488564</mixed-citation></ref><ref id="hanspub.21782-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jankovic, J., Kenney, C., Grafe, S., Goertelmeyer, R. and Comes, G. (2009) Relationship between Various Clinical Outcome Assessments in Patients with Blepharospasm. Movement Disorders: Official Journal of the Movement Disorder Society, 24, 407-413. &lt;br&gt;https://doi.org/10.1002/mds.22368</mixed-citation></ref><ref id="hanspub.21782-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mezaki, T., Kaji, R., Brin, M.F., Hirota-Katayama, M., Kubori, T., Shimizu, T., et al. (1999) Combined Use of Type A and F Botulinum Toxins for Blepharospasm: A Double-Blind Controlled Trial. Movement Disorders: Official Journal of the Movement Disorder Society, 14, 1017-1020.  
&lt;br&gt;https://doi.org/10.1002/1531-8257(199911)14:6&lt;1017::AID-MDS1018&gt;3.0.CO;2-3</mixed-citation></ref><ref id="hanspub.21782-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sung, Y., Nam, S.M. and Lew, H. (2015) Clinical Outcomes of Individualized Botulinum Neurotoxin Type A Injection Techniques in Patients with Essential Blepharospasm. Korean Journal of Ophthalmology: KJO, 29, 115-120.  
&lt;br&gt;https://doi.org/10.3341/kjo.2015.29.2.115</mixed-citation></ref><ref id="hanspub.21782-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Karttunen, P., Tukiainen, H., Silvasti, M. and Kolonen, S. (1987) Antitussive Effect of Dextromethorphan and Dextromethorphan-Salbutamol Combination in Healthy Volunteers with Artificially Induced Cough. Respiration; International Review of Thoracic Diseases, 52, 49-53. &lt;br&gt;https://doi.org/10.1159/000195303</mixed-citation></ref><ref id="hanspub.21782-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bokesch, P.M., Marchand, J.E., Connelly, C.S., Wurm, W.H. and Kream, R.M. (1994) Dextromethorphan Inhibits Ischemia-Induced c-fos Expression and Delayed Neuronal Death in Hippocampal Neurons. Anesthesiology, 81, 470-477. &lt;br&gt;https://doi.org/10.1097/00000542-199408000-00026</mixed-citation></ref><ref id="hanspub.21782-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Huang, E.Y., Liu, T.C. and Tao, P.L. (2003) Co-Administration of Dextromethorphan with Morphine Attenuates Morphine Rewarding Effect and Related Dopamine Releases at the Nucleus Accumbens. Naunyn-Schmiedeberg’s Archives of Pharmacology, 368, 386-392. &lt;br&gt;https://doi.org/10.1007/s00210-003-0803-7</mixed-citation></ref><ref id="hanspub.21782-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.L., Hsu, K.Y., Huang, E.Y., Lu, R.B. and Tao, P.L. (2011) Low Doses of Dextromethorphan Attenuate Morphine-Induced Rewarding via the Sigma-1 Receptor at ventral Tegmental Area in Rats. Drug and Alcohol Dependence, 117, 164-169. &lt;br&gt;https://doi.org/10.1016/j.drugalcdep.2011.01.013</mixed-citation></ref><ref id="hanspub.21782-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ohi, Y., Tsunekawa, S. and Haji, A. (2011) Dextromethorphan Inhibits the Glutamatergic Synaptic Transmission in the Nucleus Tractus Solitarius of Guinea Pigs. Journal of Pharmacological Sciences, 116, 54-62.  
&lt;br&gt;https://doi.org/10.1254/jphs.11008FP</mixed-citation></ref></ref-list></back></article>